Breast Cancer | Topics

 
Trastuzumab Deruxtecan May Effectively Treat CNS-Metastatic HER2+ Breast Cancer While Maintaining QOL
October 05, 2022

A secondary end point analysis of the phase 2 TUXEDO-1 trial found that trastuzumab deruxtecan improved outcomes without significantly impacting quality of life for patients with HER2-positive breast cancer with CNS metastases.

Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and More
October 02, 2022

Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.

Senthil Damodaran, MD, PhD, on How Lasofoxifene Combo May Fulfill Unmet Needs in ESR1+ Breast Cancer After CDK4/6
September 27, 2022

Patients with locally advanced or metastatic ESR1-mutant, estrogen receptor–positive, HER2-negative breast cancer who have progressed on a CDK4/6 inhibitor may benefit from treatment with lasofoxifene and abemaciclib.

Sacituzumab Govitecan Improved Outcomes in HR+/HER2– Metastatic Breast Cancer Vs Physician’s Choice
September 27, 2022

Results from a post-hoc subgroup analysis of the phase 3 TROPiCS-02 study indicated that sacituzumab govitecan improved efficacy outcomes vs physician’s choice of treatment in HER2-low and HER2 immunohistochemistry 0, hormone receptor–positive metastatic breast cancer.

Angela DeMichele, MD, MSCE, Talks Changes to the Treatment Paradigm Resulting From I-SPY2 in Early Breast Cancer
September 17, 2022

Angela DeMichele, MD, MSCE, discussed how the standard of care can be shifted based on the results of the phase 2 I-SPY2 trial investigating novel neoadjuvant treatment strategies in early breast cancer.

Survival Benefit Observed With Ribociclib Plus Endocrine Therapy in Advanced HR+/HER2– Breast Cancer With Visceral Metastases
September 13, 2022

A pooled exploratory analysis of phase 3 trials found statistically significant progression-free survival and overall survival benefits with ribociclib/endocrine therapy for patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Naoto Ueno, MD, PhD, Discusses QOL With Trastuzumab Deruxtecan in HR+, HER2-Low Metastatic Breast Cancer
September 12, 2022

Treatment with fam-trastuzumab deruxtecan-nxki yielded promising patient-reported outcomes in patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to Naoto Ueno, MD, PhD.

Trastuzumab Deruxtecan Demonstrates Promising QOL in HR+, HER2-Low Breast Cancer
September 11, 2022

Findings from the DESTINY-Breast04 trial indicated that patients with hormone receptor–positive, HER2-low metastatic breast cancer experienced promising quality of life following treatment with fam-trastuzumab deruxtecan-nxki.

Amcenestrant and Endocrine Therapy Led to Similar Risk of Disease Progression in Endocrine-Resistant, ER-Positive Advanced Breast Cancer
September 10, 2022

The phase 2 AMEERA-3 trial revealed no progression-free survival benefit of amcenestrant vs physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor–positive, HER2-negative advanced breast cancer.

Efficacy of Sacituzumab Govitecan in HER2-low/IHC0 Metastatic Breast Cancer Appears Positive in TROPiCS-02
September 10, 2022

Progression-free survival and response results presented from the phase 3 TROPiCS-02 trial at 2022 ESMO indicated sacituzumab govitecan-hziy may be favorable vs physician’s choice of treatment for HER2-low or HER2 IHC0, hormone receptor¬–positive metastatic breast cancer.